X4 Pharmaceuticals Inc Stock Price, News & Analysis

X4 Pharmaceuticals (XFOR) presented positive Phase 2 trial data for mavorixafor in treating chronic neutropenia at the 30th EHA Congress. The 6-month study involving 23 participants demonstrated that oral, once-daily mavorixafor effectively increased absolute neutrophil count (ANC) both as monotherapy and in combination with G-CSF. Key findings showed that patients with severe chronic neutropenia achieved nearly 3-fold increases in mean ANC levels, and 89% of participants were able to reduce or discontinue injectable G-CSF while maintaining normal ANC levels. The drug was well-tolerated with no drug-related serious adverse events. A sub-study revealed that treated patients' functional neutrophil levels were comparable to healthy donors. The company is currently conducting a global Phase 3 pivotal trial, expected to complete enrollment in Q3/Q4 2025.

X4 Pharmaceuticals (XFOR) announced that the FDA has granted Fast Track designation to mavorixafor for treating chronic neutropenia (CN). Mavorixafor, an oral CXCR4 antagonist, is currently in a global Phase 3 clinical trial (4WARD). The drug previously received Fast Track designation and FDA approval for WHIM syndrome in April 2024. The company expects full trial enrollment in Q3/Q4 2025 with top-line data anticipated in late 2026. Currently, the only FDA-approved treatment for CN is injectable G-CSF, which has significant side effects including bone pain, splenomegaly, and increased leukemia risk. X4 believes oral mavorixafor could offer better disease control with reduced treatment burden for CN patients.

X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan. The awards consist of stock options to purchase 5,545 shares of common stock, granted on May 30, 2025. The options have a ten-year term with an exercise price of $3.40 per share, matching X4's closing stock price on the grant date. The vesting schedule spans four years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months, contingent on continued employment. These grants, approved by X4's Compensation Committee, were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new employee recruitment.

X4 Pharmaceuticals (XFOR) announced the acceptance of two abstracts for poster presentation at the 30th Annual Congress of the European Hematology Association (EHA) in Milan. The presentations will showcase results from their completed Phase 2 trial of mavorixafor in treating primary chronic neutropenic (CN) disorders.

The six-month, open-label clinical trial enrolled 23 participants with idiopathic, congenital, or cyclic chronic neutropenia. Key findings include meaningful and durable increases in functional neutrophils with once-daily oral mavorixafor, and most physicians and participants opted to reduce G-CSF dosing when using mavorixafor in combination therapy. Mavorixafor represents the first innovation in CN treatment in over 30 years and could become the first oral treatment available if approved.

X4 Pharmaceuticals (XFOR) reported Q1 2025 financial results and corporate updates. The company's 4WARD Phase 3 trial for chronic neutropenia is progressing well, with full enrollment expected in Q3/Q4 2025 and top-line data in 2H 2026. X4 reported net revenue of $28.8 million, including $27.9 million from the Norgine agreement and $0.9 million from XOLREMDI product sales. Since its May 2024 launch, XOLREMDI has generated $3.5 million in U.S. sales. The company ended Q1 with $87.7 million in cash, sufficient to fund operations into 1H 2026. Key developments include EMA acceptance of mavorixafor's MAA for WHIM syndrome, new international partnerships with Norgine Pharma UK and taiba rare, and a strategic restructuring expected to reduce annual spending by $30-35 million. The company recently completed a 1-for-30 reverse stock split.

X4 Pharmaceuticals (Nasdaq: XFOR), a biotechnology company focused on rare immune system diseases, has scheduled its first-quarter 2025 financial results announcement and corporate update for May 1, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT on the same day.

Investors and interested parties can access the conference call by dialing 1-800-343-4849 (US) or 1-203-518-9848 (International) using the conference ID: X4PHARMA. A live webcast will be available through X4's investor relations website, with a replay accessible after the call.

X4 Pharmaceuticals (XFOR) has announced a 1-for-30 reverse stock split effective April 28, 2025. The split will reduce outstanding shares from approximately 173.6 million to 5.8 million, with trading on Nasdaq Capital Market beginning on the same date.

This strategic move comes after receiving a Nasdaq deficiency notice on August 13, 2024, due to the stock price falling below the required $1.00 minimum bid for 30 consecutive business days. While X4 received an additional compliance period until August 11, 2025, the reverse split aims to increase the stock price and maintain Nasdaq listing requirements.

The split will proportionally adjust equity incentive plans, stock options, and warrants. Stockholders with fractional shares will receive cash in lieu, and those with book-entry shares will see changes reflected in their accounts after April 28, 2025.

X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan. The awards, effective January 31, 2025, consist of options to purchase 450,471 shares of X4's common stock at an exercise price of $0.2030 per share, matching the closing price on April 22, 2025.

The stock options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), feature a ten-year term and a four-year vesting schedule. The vesting structure includes 25% of shares vesting after 12 months, followed by monthly vesting of the remaining shares over 36 months, contingent on continued employment.

X4 Pharmaceuticals (XFOR) reported its Q4 and full year 2024 financial results, highlighting significant progress in commercializing XOLREMDI® for WHIM syndrome and advancing clinical trials. Key financial metrics include $2.6 million in XOLREMDI® net revenues since its May 2024 launch, and $102.8 million in cash position as of December 31, 2024.

The company's Phase 3 4WARD trial for chronic neutropenia has reached ~90% site activation, with full enrollment expected in Q3/Q4 2025 and top-line data anticipated in 2H 2026. Notable achievements include the sale of a priority review voucher for $105 million and strategic partnerships in EU/ANZ and MENA regions, with Norgine Pharma providing a €28.5 million upfront payment.

Financial results show R&D expenses of $81.6 million and SG&A expenses of $61.5 million for 2024. The company implemented a strategic restructuring in February 2025, expected to reduce annual spending by $30-35 million. X4 projects sufficient funding into first half of 2026.